What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Cancer
His primary scientific interests are in Internal medicine, Gastroenterology, Ulcerative colitis, Inflammatory bowel disease and Crohn's disease.
Subrata Ghosh combines subjects such as Placebo, Surgery and Immunology with his study of Internal medicine.
His research investigates the connection with Gastroenterology and areas like Crohn's Disease Activity Index which intersect with concerns in Methotrexate and Adverse effect.
The Ulcerative colitis study which covers Colitis that intersects with Mesalazine and Pharmacology.
In his study, which falls under the umbrella issue of Inflammatory bowel disease, Combination therapy is strongly linked to Review article.
Crohn's disease is the subject of his research, which falls under Disease.
His most cited work include:
- Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review (2933 citations)
- Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies (1327 citations)
- Ustekinumab induction and maintenance therapy in refractory Crohn's disease. (730 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Gastroenterology, Ulcerative colitis, Inflammatory bowel disease and Crohn's disease.
His study in Internal medicine is interdisciplinary in nature, drawing from both Placebo and Surgery.
His studies in Gastroenterology integrate themes in fields like Colonoscopy, Azathioprine and Endoscopy.
His Ulcerative colitis study combines topics from a wide range of disciplines, such as Chromoendoscopy, Adalimumab, Infliximab and Colitis.
His Inflammatory bowel disease study combines topics in areas such as Physical therapy and Intensive care medicine.
His research on Crohn's disease often connects related areas such as Immunology.
He most often published in these fields:
- Internal medicine (43.19%)
- Gastroenterology (27.35%)
- Ulcerative colitis (26.39%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (43.19%)
- Inflammatory bowel disease (22.74%)
- Ulcerative colitis (26.39%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease and Gastroenterology are his primary areas of study.
His study explores the link between Internal medicine and topics such as Placebo that cross with problems in Adverse effect.
His studies deal with areas such as Colorectal cancer, Dysplasia and Cohort as well as Inflammatory bowel disease.
His Ulcerative colitis research includes elements of Colonoscopy, Chromoendoscopy and Histology.
His Crohn's disease study frequently links to other fields, such as Intensive care medicine.
Subrata Ghosh works mostly in the field of Gastroenterology, limiting it down to topics relating to Calprotectin and, in certain cases, Feces, as a part of the same area of interest.
Between 2017 and 2021, his most popular works were:
- Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. (251 citations)
- Implications of COVID-19 for patients with pre-existing digestive diseases. (186 citations)
- British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. (117 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
Subrata Ghosh focuses on Inflammatory bowel disease, Internal medicine, Crohn's disease, Ulcerative colitis and Gastroenterology.
His research on Inflammatory bowel disease concerns the broader Disease.
As a member of one scientific family, he mostly works in the field of Internal medicine, focusing on Endocrinology and, on occasion, Inflammation, Occludin and Experimental colitis.
His work in Crohn's disease covers topics such as Adverse effect which are related to areas like Placebo, Ustekinumab, Clinical endpoint and Crohn's Disease Activity Index.
His Ulcerative colitis research integrates issues from Adalimumab, Infliximab, Granuloma, Paneth cell and Cohort.
His Gastroenterology research is multidisciplinary, incorporating elements of Randomized controlled trial, Maintenance therapy and Induction therapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
